Dyslipidemia

1. Auflage 2011
ISBN: 978-0-19-974286-8
Verlag: OUP US

Buch, Englisch, 144 Seiten, Format (B × H): 127 mm x 203 mm, Gewicht: 171 g

Reihe: Oxford American Cardiology Library

Authored by a renowned international group of experts on dyslipidemia.
Chapters include vignettes to enhance clinical relevance.

Dyslipidemia affects almost half of American adults and is the most prevalent manageable risk factor for atherosclerosis. Lipid disorders often co-occur with other prevalent conditions such as diabetes and kidney disease; they are also often a concern with certain medication regimens (such as anti-retroviral and certain anti-psychotic agents). Proper treatment of dyslipidemia can reduce the risk of peripheral arterial disease, revascularization procedures, nonfatal myocardial infarction, stroke, and cardiac death. However, only 20% of adults meet the national guidelines for cholesterol control.

As part of the Oxford American Cardiology Library, this practical handbook is designed to serve as a concise yet authoritative resource on diagnosing and treating dyslipidemia. The book is tailored to the needs of busy health care professionals treating patients in various clinical settings, and focuses on presenting essential information to clinicians who are at the forefront of the diagnosis and management of dyslipidemia. Featuring evidence-based, concise yet comprehensive discussion of key clinical concepts in addition to numerous figures, tables and illustrations, this pocket-sized handbook will serve as an invaluable guide to healthcare professionals.

Zielgruppe

Cardiologists; cardiology trainees and residents.

Autoren/Hrsg.

Baliga, Ragavendra R.

Cannon, Christopher P.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Kardiologie, Angiologie, Phlebologie

Inhaltsverzeichnis

Contributors
1. LDL Cholesterol
2. HDL Cholesterol

3. Non-HDL Cholesterol
4. Use of High Sensitivity C-reactive Protein for Risk Assessment
5. Advanced Lipoprotein Testing: Assessment of Cardiovascular Risk and Therapy Beyond Standard Lipid Measurements
6. Stratification of Dyslipidemic Risk
7. Drugs for Treatment of Blood Lipoprotein Abnormalities
Index

Über Autor(innen)

Edited by Ragavendra R. Baliga, Director of Cardiovascular Medicine, The Ohio State University Medical Center, and Edited by Christopher P. Cannon, Associate Professor of Medicine, Harvard Medical School

Ragavendra R. Baliga, MD, MBA, FACC, FRCP, is Director of Cardiovascular Medicine at The Ohio State University Medical Center in Columbus, Ohio. Christopher P. Cannon, MD, is Associate Professor of Medicine at Harvard Medical School and Associate Physician, Cardiovascular Division, at Brigham and Women's Hospital in Boston, Massachusetts.

Contributors:
Philip Barter, MD, PhD; Vera Bittner, MD, MSPH; Roger S. Blumenthal, MD; William Virgil Brown, MD; Catherine Y. Campbell, MD; Edwin E. Ferguson, MD; Antonio M. Gotto, Jr., MD, DPhil; Garth Graham, MD; Charles Harper, MD; William B. Kannel, MD, FACC; Kerunne Ketlogetswe, MD; Patrick E. McBride, MD, MPH; Jennifer Moon, PhD; Samia Mora, MD, MHS; Kiran Musunuru, MD, PhD; Kerry-Anne Rye, PhD; Donald A. Wiebe, PhD